• Reported Q1 2025 financial results, including net sales of $556k
• Continued progress on DurAVR® THV development, including preparation for Pivotal Trial
• Received $80M in net proceeds from IPO, with $20.8M used for DurAVR® development

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported its financial results for the first quarter of 2025. The company reported net sales of $556k for the quarter. Anteris continued to make progress on the development of its lead product, the DurAVR® Transcatheter Heart Valve (THV), using $20.8M of the $80M in net proceeds from its initial public offering in December 2024 to fund the ongoing development of DurAVR® THV and the preparation and enrollment of the Pivotal Trial for treating severe aortic stenosis. An additional $10.5M was used for net working capital and other general corporate purposes, including the repayment of $6.4M in debt. During the quarter, the company made $1.77M in payments to related parties and their associates, which included director fees, company secretarial fees, and executive compensation. Anteris remains focused on advancing the DurAVR® THV program and expanding its global manufacturing capacity to support the commercialization of this innovative medical device.